XML 86 R31.htm IDEA: XBRL DOCUMENT v3.19.3
Fair Value Measurements (Tables)
9 Months Ended
Sep. 30, 2019
Fair Value Disclosures [Abstract]  
Schedule of Financial Instrument Measured on Recurring Basis

The valuation methodologies used for the Company’s financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the tables below:

 

    As of September 30, 2019     Fair Value Measurements  
    Carrying     Fair     As of September 30, 2019  
    Amount     Value     Level 1     Level 2     Level 3  
                (unaudited)              
Liabilities:                                        
Contingent consideration:                                        
Asuragen (1)   $ 3,024     $ 3,024     $        -     $      -     $ 3,024  
Other long-term liabilities:                                        
Warrant liability (2)     326       326       -       -       326  
    $ 3,350     $ 3,350     $ -     $ -     $ 3,350  

 

    As of December 31, 2018     Fair Value Measurements  
    Carrying     Fair     As of December 31, 2018  
    Amount     Value     Level 1     Level 2     Level 3  
Liabilities:                              
Contingent consideration:                                        
Asuragen (1)   $ 3,127     $ 3,127     $    -     $    -     $ 3,127  
Other long-term liabilities:                                        
Warrant liability (2)     361       361       -       -       361  
    $ 3,488     $ 3,488     $ -     $ -     $ 3,488  

 

(1)(2) See Note 9, Accrued Expenses and Long-Term Liabilities

Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation

A roll forward of the carrying value of the Contingent Consideration Liability and the Underwriters’ Warrants to September 30, 2019 is as follows:

 

                      Cancellation     Adjustment        
                      of Obligation/     to Fair Value/        
    December 31, 2018     Payments     Accretion     Conversions
Exercises
    Mark to
Market
    September 30, 2019  
    (unaudited)  
Asuragen   $ 3,127     $ (434 )   $ 331     $    -     $ -     $ 3,024  
                                                 
Underwriters Warrants     361       -       -       -       (35 )     326  
    $ 3,488     $ (434 )   $ 331     $ -     $ (35 )   $ 3,350